Skip to main content
. 2017 Dec 12;9(1):842–852. doi: 10.18632/oncotarget.23182

Figure 2. Expression of FoxM1 was distinct in different molecular subtypes of BC patients.

Figure 2

Global significant different between groups was assessed by Welch’s test to generate p value, along with Dunnett-Tukey-Kramer’s tests for pairwise comparison when a global significant difference exists (p < 0.05). (A) The mRNA expression level of FoxM1 in BC patients with ER (−) and ER (+). (B) The mRNA expression level of FoxM1 in BC patients with PR (−) and PR (+). (C) The mRNA expression level of FoxM1 in BC patients with HER-2 (−) and HER-2(+). (D) The mRNA expression level of FoxM1 in a variety of breast cancer subtype. (E) The mRNA expression level of FoxM1 in TNBC or NOT TNBC patients. (F) The mRNA expression level of FoxM1 in Basal-like or NOT Basal-like breast cancer subtype. (G) The mRNA expression level of FoxM1 in Basal-like or Luminal-like breast cancer subtype. (H) The mRNA expression level of FoxM1 in different Nottingham Prognostic Index(NPI) BC subgroups. (I) The mRNA expression level of FoxM1 in different Scarff Bloom & Richardson grade status (SBR) BC subgroups.